---
title: Effect of Vitamin D on the Size of Fibroids in Women With Vitamin D Deficiency
nct_id: NCT03991078
overall_status: COMPLETED
sponsor: Fundación IVI
study_type: OBSERVATIONAL
primary_condition: Size of the Uterine Fibroids
countries: Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03991078.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03991078"
ct_last_update_post_date: 2025-03-13
last_seen_at: "2026-05-12T07:33:52.613Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Vitamin D on the Size of Fibroids in Women With Vitamin D Deficiency

**Official Title:** Pilot Clinical Study to Evaluate the Effect of Vitamin D on the Size of Fibroids in Women With Vitamin D Deficiency

**NCT ID:** [NCT03991078](https://clinicaltrials.gov/study/NCT03991078)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 15
- **Lead Sponsor:** Fundación IVI
- **Collaborators:** Hospital Universitario La Fe
- **Conditions:** Size of the Uterine Fibroids
- **Start Date:** 2019-07-09
- **Completion Date:** 2024-12-25
- **CT.gov Last Update:** 2025-03-13

## Brief Summary

Vitamin D supplementation in patients with uterine fibroids who present hypovitaminosis D to re-establish their normal serum values could stabilize the size of the uterine fibroids and thus prevent their growth or reduce their size thanks to the anti-proliferative action of Vitamin D on the myoma cells.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnosed with at least one fibroid \> 3 cm
* With hypovitaminosis D (25(OH)D \< 30 ng/ml)
* BMI \< 30
* No hormonal treatment in the 3 months prior to the ultrasound study

Exclusion Criteria:

* Black race
* Symptomatic fibroids subsidiary to hormonal or surgical treatment
* Desire of gestation in the next 6 months
* Presence of degenerating adenomyosis or fibroids
* Treatment with sexual hormones: mifepristone, aGnRH or any other medication that may interfere with fibroids.
* History of neoplasia of gynecological origin and/or existence of uterine malformations.
* Hypercalcemia or abnormal liver or kidney function is present
```

## Primary Outcomes

- **volume of the uterine fibroids** _(time frame: 3 months)_

## Locations (1)

- Fundacion IVI, Valencia, Spain

## Recent Field Changes (last 30 days)

- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.fundacion ivi|valencia||spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03991078.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03991078*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*